Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus

[1]  A. Barbaud,et al.  Skin tests in the work‐up of cutaneous adverse drug reactions: A review and update , 2022, Contact dermatitis.

[2]  T. Dowlut-McElroy,et al.  Vulvovaginal involvement in pediatric Stevens-Johnson syndrome: A case series. , 2021, Journal of pediatric and adolescent gynecology.

[3]  O. Dereure,et al.  Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  R. Stern,et al.  Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus , 2021, The British journal of dermatology.

[5]  H. Lee,et al.  Spectrum of Nail Sequelae in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 2020, JAMA dermatology.

[6]  J. Lefaucheur,et al.  Chronic pain: a long‐term sequela of epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) – prevalence, clinical characteristics and risk factors , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  P. Wolkenstein,et al.  [Advances in understanding of the pathophysiology of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)]. , 2020, Annales de dermatologie et de venereologie.

[8]  L. French,et al.  Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  James X. Sun,et al.  Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. , 2020, Journal of the American Academy of Dermatology.

[10]  P. Wolkenstein,et al.  Health‐related quality of life and long‐term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients , 2020, The British journal of dermatology.

[11]  P. Wolkenstein,et al.  Individual‐ and hospital‐level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012–2016 , 2020, The British journal of dermatology.

[12]  P. Wolkenstein,et al.  Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture–recapture estimate , 2020, The British journal of dermatology.

[13]  Behnam Masmouei,et al.  The effect of progressive muscle relaxation on anxiety and sleep quality in burn patients: A randomized clinical trial. , 2019, Burns : journal of the International Society for Burn Injuries.

[14]  S. Austin,et al.  Bronchiolitis obliterans as a long‐term sequela of Stevens–Johnson syndrome and toxic epidermal necrolysis in children , 2019, Clinical and experimental dermatology.

[15]  M. Sengoelge,et al.  Psychosocial Interventions Targeting Recovery in Child and Adolescent Burns: A Systematic Review. , 2019, Journal of pediatric psychology.

[16]  J. Caubet,et al.  Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug. , 2019, Current pharmaceutical design.

[17]  P. Wolkenstein,et al.  Trends in mortality rates for Stevens–Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017 , 2019, The British journal of dermatology.

[18]  P. Wolkenstein,et al.  Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae , 2019, The British journal of dermatology.

[19]  M. Pirmohamed,et al.  Controversies in drug allergy: Testing for delayed reactions. , 2019, The Journal of allergy and clinical immunology.

[20]  P. Wolkenstein,et al.  Post‐traumatic stress disorder in Stevens–Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients , 2018, The British journal of dermatology.

[21]  E. Ramírez,et al.  Assessment of drug causality in SJS/TEN: concordance between lymphocyte transformation test and ALDEN. , 2019, Allergy.

[22]  C. Sotozono,et al.  Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage. , 2018, Investigative ophthalmology & visual science.

[23]  P. Tuchinda,et al.  Evaluation of a lymphocyte transformation test and cytokine detection assay to identify phenytoin and carbamazepine provoked DRESS or SJS/TEN in epilepsy patients , 2018, International immunopharmacology.

[24]  C. Bodemer,et al.  Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins) , 2018, Orphanet Journal of Rare Diseases.

[25]  E. Phillips,et al.  The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. , 2017, The journal of allergy and clinical immunology. In practice.

[26]  D. Canning,et al.  Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2017, Journal of pediatric urology.

[27]  D. Creamer,et al.  Long‐term complications of Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow‐up , 2017, The British journal of dermatology.

[28]  M. Salman,et al.  Vaginal Reconstruction for Vaginal Obliteration Secondary to Stevens Johnson Syndrome: A Case Report and Review of Literature. , 2017, Oman medical journal.

[29]  A. Feinstein,et al.  Major psychological complications and decreased health‐related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis , 2016, The British journal of dermatology.

[30]  P. Dziewulski,et al.  UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[31]  P. Dziewulski,et al.  U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.

[32]  C. Chu,et al.  Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. , 2016, Acta dermato-venereologica.

[33]  P. Wolkenstein,et al.  Facial Scars following Toxic Epidermal Necrolysis: Role of Adnexal Involvement? , 2016, Dermatology.

[34]  L. J. Chen,et al.  Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis. , 2015, The ocular surface.

[35]  J. Roujeau,et al.  Stevens–Johnson syndrome and toxic epidermal necrolysis: follow‐up of pulmonary function after remission , 2015, The British journal of dermatology.

[36]  A. Villa,et al.  Diagnosis and management of xerostomia and hyposalivation , 2014, Therapeutics and clinical risk management.

[37]  C. Sotozono,et al.  Tear exchangeable limbal rigid contact lens for ocular sequelae resulting from Stevens-Johnson syndrome or toxic epidermal necrolysis. , 2014, American journal of ophthalmology.

[38]  P. Wolkenstein,et al.  Severe Cutaneous Adverse Reactions to Drugs: From Patients to the National Office for Compensation of Medical Accidents , 2014, Dermatology.

[39]  S. W. Kim,et al.  Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. , 2013, American journal of ophthalmology.

[40]  L. Naldi,et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[41]  P. Prabhasawat,et al.  Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[42]  B. Milpied,et al.  A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions , 2013, The British journal of dermatology.

[43]  R. Hui,et al.  A patch testing and cross‐sensitivity study of carbamazepine‐induced severe cutaneous adverse drug reactions , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  M. Laufer,et al.  Prevention of vulvovaginal sequelae in stevens-johnson syndrome and toxic epidermal necrolysis. , 2011, Reviews in obstetrics & gynecology.

[45]  S. Doan,et al.  Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2009, American journal of ophthalmology.

[46]  J. Roujeau,et al.  Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. , 2009, Archives of dermatology.

[47]  G. Soubrane,et al.  Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2009, Archives of dermatology.

[48]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[49]  T. Shiohara,et al.  Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption , 2007, Allergy.

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  J. Roujeau,et al.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.

[52]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[53]  J. Roujeau,et al.  Patch testing in severe cutaneous adverse drug reactions, including Stevens‐Johnson syndrome and toxic epidermal necrolysis , 1996, Contact dermatitis.

[54]  C. Foster,et al.  Penetrating keratoplasty in cicatrizing conjunctival diseases. , 1995, Ophthalmology.

[55]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.